{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:32Z","timestamp":1792979912963,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes of Health Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship","award":["F32CA278313"],"award-info":[{"award-number":["F32CA278313"]}]},{"name":"National Institute of General Medical Sciences of the National Institutes of Health","award":["T32GM136554"],"award-info":[{"award-number":["T32GM136554"]}]},{"name":"National Cancer Institute","award":["R01282467"],"award-info":[{"award-number":["R01282467"]}]},{"name":"U.S. Department of Defense Career Development Award","award":["W81XWH-21-1-0396\/CD201061"],"award-info":[{"award-number":["W81XWH-21-1-0396\/CD201061"]}]},{"DOI":"10.13039\/100020187","name":"Macy Easom Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020187","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helis Foundation"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180674"],"award-info":[{"award-number":["RP180674"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31141-8","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:54:50Z","timestamp":1764896090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dinaciclib improves treatment response in chemoresistant hepatoblastoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Brian T.","family":"Hickner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Badachhape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores H.","family":"L\u00f3pez-Terrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Woodfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev A.","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"31141_CR1","volume-title":"StatPearls","author":"SR Musick","year":"2025","unstructured":"Musick, S. R., Smith, M., Rouster, A. S. & Babiker, H. M. Hepatoblastoma. In StatPearls (eds Musick, S. R. et al.) (StatPearls Publishing LLC, 2025)."},{"issue":"3","key":"31141_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/jhep.2003.50375","volume":"38","author":"A Darbari","year":"2003","unstructured":"Darbari, A., Sabin, K. M., Shapiro, C. N. & Schwarz, K. B. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 38 (3), 560\u2013566. https:\/\/doi.org\/10.1053\/jhep.2003.50375 (2003).","journal-title":"Hepatology"},{"key":"31141_CR3","volume-title":"Liver Cancer","author":"J Hager","year":"2021","unstructured":"Hager, J. & Sergi, C. M. Hepatoblastoma. In Liver Cancer (ed. Sergi, C. M.) (Exon Publications, 2021)."},{"issue":"2","key":"31141_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.surg.2012.11.006","volume":"153","author":"RJ Cruz Jr","year":"2013","unstructured":"Cruz, R. J. Jr. et al. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. Surgery 153 (2), 150\u2013159. https:\/\/doi.org\/10.1016\/j.surg.2012.11.006 (2013).","journal-title":"Surgery"},{"issue":"11","key":"31141_CR5","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.21873\/anticanres.11143","volume":"36","author":"A Garnier","year":"2016","unstructured":"Garnier, A., Ilmer, M., Kappler, R. & Berger, M. Therapeutic innovations for targeting hepatoblastoma. Anticancer Res. 36 (11), 5577\u20135592. https:\/\/doi.org\/10.21873\/anticanres.11143 (2016).","journal-title":"Anticancer Res."},{"issue":"22","key":"31141_CR6","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1200\/jco.19.01067","volume":"38","author":"E Hiyama","year":"2020","unstructured":"Hiyama, E. et al. Outcome and late complications of hepatoblastomas treated using the Japanese study group for pediatric liver tumor 2 protocol. J. Clin. Oncol. 38 (22), 2488\u20132498. https:\/\/doi.org\/10.1200\/jco.19.01067 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"31141_CR7","doi-asserted-by":"publisher","first-page":"e30302","DOI":"10.1002\/pbc.30302","volume":"70","author":"S Srinivasan","year":"2023","unstructured":"Srinivasan, S. et al. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach. Pediatr. Blood Cancer 70 (7), e30302. https:\/\/doi.org\/10.1002\/pbc.30302 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"31141_CR8","doi-asserted-by":"publisher","first-page":"113583","DOI":"10.1016\/j.ejca.2024.113583","volume":"200","author":"A Pire","year":"2024","unstructured":"Pire, A. et al. Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival. Eur. J. Cancer 200, 113583. https:\/\/doi.org\/10.1016\/j.ejca.2024.113583 (2024).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"31141_CR9","doi-asserted-by":"publisher","first-page":"e2148013","DOI":"10.1001\/jamanetworkopen.2021.48013","volume":"5","author":"S Zhou","year":"2022","unstructured":"Zhou, S. et al. Independent assessment of the children\u2019s hepatic tumors international collaboration risk stratification for hepatoblastoma and the association of tumor histological characteristics with prognosis. JAMA Netw. Open 5 (2), e2148013. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48013 (2022).","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"31141_CR10","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cell.2016.11.034","volume":"167","author":"MP Swaffer","year":"2016","unstructured":"Swaffer, M. P., Jones, A. W., Flynn, H. R., Snijders, A. P. & Nurse, P. CDK substrate phosphorylation and ordering the cell cycle. Cell 167 (7), 1750-1761.e16. https:\/\/doi.org\/10.1016\/j.cell.2016.11.034 (2016).","journal-title":"Cell"},{"issue":"11","key":"31141_CR11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nrm2510","volume":"9","author":"H Hochegger","year":"2008","unstructured":"Hochegger, H., Takeda, S. & Hunt, T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all?. Nat. Rev. Mol. Cell Biol. 9 (11), 910\u2013916. https:\/\/doi.org\/10.1038\/nrm2510 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"31141_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/cancers6010079","volume":"6","author":"X Bisteau","year":"2014","unstructured":"Bisteau, X., Caldez, M. J. & Kaldis, P. The complex relationship between liver cancer and the cell cycle: A story of multiple regulations. Cancers (Basel) 6 (1), 79\u2013111. https:\/\/doi.org\/10.3390\/cancers6010079 (2014).","journal-title":"Cancers (Basel)"},{"key":"31141_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143380","author":"JT Thiel","year":"2022","unstructured":"Thiel, J. T., Daigeler, A., Kolbenschlag, J., Rachunek, K. & Hoffmann, S. The role of CDK pathway dysregulation and its therapeutic potential in soft tissue sarcoma. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14143380 (2022).","journal-title":"Cancers (Basel)"},{"key":"31141_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103219","author":"B Garc\u00eda-Reyes","year":"2018","unstructured":"Garc\u00eda-Reyes, B. et al. The emerging role of cyclin-dependent kinases (CDKs) in pancreatic ductal adenocarcinoma. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms19103219 (2018).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"31141_CR15","doi-asserted-by":"publisher","first-page":"e28221","DOI":"10.1002\/pbc.28221","volume":"67","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. CDK9 is dispensable for YAP-driven hepatoblastoma development. Pediatr. Blood Cancer 67 (5), e28221. https:\/\/doi.org\/10.1002\/pbc.28221 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"31141_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061960","author":"L Ding","year":"2020","unstructured":"Ding, L. et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21061960 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"31141_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14 (2), 130\u2013146. https:\/\/doi.org\/10.1038\/nrd4504 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31141_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski, R. Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol. Res. 139, 471\u2013488. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.035 (2019).","journal-title":"Pharmacol. Res."},{"issue":"3","key":"31141_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.Cd-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y. & Ashworth, A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 10 (3), 351\u2013370. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-0528 (2020).","journal-title":"Cancer Discov."},{"issue":"16","key":"31141_CR20","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2017","unstructured":"Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene 36 (16), 2255\u20132264. https:\/\/doi.org\/10.1038\/onc.2016.379 (2017).","journal-title":"Oncogene"},{"issue":"23","key":"31141_CR21","first-page":"4533","volume":"19","author":"R Li","year":"2015","unstructured":"Li, R., Liu, G. Z., Luo, S. Y., Chen, R. & Zhang, J. X. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer. Eur. Rev. Med. Pharmacol. Sci. 19 (23), 4533\u20134541 (2015).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"6","key":"31141_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/cts.12802","volume":"13","author":"AG Murphy","year":"2020","unstructured":"Murphy, A. G. et al. A phase I study of dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer. Clin. Transl. Sci. 13 (6), 1178\u20131188. https:\/\/doi.org\/10.1111\/cts.12802 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"31141_CR23","doi-asserted-by":"publisher","first-page":"29090","DOI":"10.1038\/srep29090","volume":"6","author":"Z Chen","year":"2016","unstructured":"Chen, Z. et al. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci. Rep. 6, 29090. https:\/\/doi.org\/10.1038\/srep29090 (2016).","journal-title":"Sci. Rep."},{"issue":"2","key":"31141_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1158\/1535-7163.Mct-19-0451","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Rational combination therapy for melanoma with dinaciclib by targeting BAK-dependent cell death. Mol. Cancer Ther. 19 (2), 627\u2013636. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-0451 (2020).","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"31141_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/hep.0000000000000601","volume":"80","author":"M Failli","year":"2024","unstructured":"Failli, M. et al. Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response. Hepatology 80 (1), 55\u201368. https:\/\/doi.org\/10.1097\/hep.0000000000000601 (2024).","journal-title":"Hepatology"},{"key":"31141_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.003","author":"AF Espinoza","year":"2024","unstructured":"Espinoza, A. F. et al. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.003 (2024).","journal-title":"J. Hepatol."},{"issue":"12","key":"31141_CR27","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1002\/cncr.30591","volume":"123","author":"HM Katzenstein","year":"2017","unstructured":"Katzenstein, H. M. et al. Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the children\u2019s oncology group AHEP0731 study committee. Cancer 123 (12), 2360\u20132367. https:\/\/doi.org\/10.1002\/cncr.30591 (2017).","journal-title":"Cancer"},{"issue":"7","key":"31141_CR28","doi-asserted-by":"publisher","first-page":"e30365","DOI":"10.1002\/pbc.30365","volume":"70","author":"PA Thompson","year":"2023","unstructured":"Thompson, P. A. et al. Vincristine\/irinotecan\/temsirolimus upfront window treatment of high-risk hepatoblastoma: a report from the children\u2019s oncology group AHEP0731 study committee. Pediatr. Blood Cancer 70 (7), e30365. https:\/\/doi.org\/10.1002\/pbc.30365 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"31141_CR29","doi-asserted-by":"publisher","DOI":"10.1242\/bio.058973","author":"SE Woodfield","year":"2022","unstructured":"Woodfield, S. E. et al. HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol. Open https:\/\/doi.org\/10.1242\/bio.058973 (2022).","journal-title":"Biol. Open"},{"issue":"4","key":"31141_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2443.2007.01065.x","volume":"12","author":"H Yamamoto","year":"2007","unstructured":"Yamamoto, H. et al. Oxidative stress induces p53-dependent apoptosis in hepatoblastoma cell through its nuclear translocation. Genes Cells 12 (4), 461\u2013471. https:\/\/doi.org\/10.1111\/j.1365-2443.2007.01065.x (2007).","journal-title":"Genes Cells"},{"issue":"1","key":"31141_CR31","doi-asserted-by":"publisher","first-page":"17751","DOI":"10.1038\/s41598-017-17665-8","volume":"7","author":"SE Woodfield","year":"2017","unstructured":"Woodfield, S. E. et al. A novel cell line based orthotopic xenograft mouse model that recapitulates human hepatoblastoma. Sci. Rep. 7 (1), 17751. https:\/\/doi.org\/10.1038\/s41598-017-17665-8 (2017).","journal-title":"Sci. Rep."},{"issue":"13","key":"31141_CR32","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/emboj.2008.121","volume":"27","author":"S Baumli","year":"2008","unstructured":"Baumli, S. et al. The structure of P-TEFb (CDK9\/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. Embo J. 27 (13), 1907\u20131918. https:\/\/doi.org\/10.1038\/emboj.2008.121 (2008).","journal-title":"Embo J."},{"key":"31141_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092181","author":"R Mandal","year":"2021","unstructured":"Mandal, R., Becker, S. & Strebhardt, K. Targeting CDK9 for anti-cancer therapeutics. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13092181 (2021).","journal-title":"Cancers (Basel)"},{"key":"31141_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/1756-0500-4-260","volume":"4","author":"R Ramakrishnan","year":"2011","unstructured":"Ramakrishnan, R., Yu, W. & Rice, A. P. Limited redundancy in genes regulated by cyclin T2 and cyclin T1. BMC Res. Notes 4, 260. https:\/\/doi.org\/10.1186\/1756-0500-4-260 (2011).","journal-title":"BMC Res. Notes"},{"issue":"11","key":"31141_CR35","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/jco.2005.03.7689","volume":"24","author":"GI Shapiro","year":"2006","unstructured":"Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (11), 1770\u20131783. https:\/\/doi.org\/10.1200\/jco.2005.03.7689 (2006).","journal-title":"J. Clin. Oncol."},{"key":"31141_CR36","doi-asserted-by":"publisher","first-page":"678559","DOI":"10.3389\/fonc.2021.678559","volume":"11","author":"AT Anshabo","year":"2021","unstructured":"Anshabo, A. T., Milne, R., Wang, S. & Albrecht, H. CDK9: A comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Front. Oncol. 11, 678559. https:\/\/doi.org\/10.3389\/fonc.2021.678559 (2021).","journal-title":"Front. Oncol."},{"issue":"11","key":"31141_CR37","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1172\/jci134132","volume":"130","author":"E Poon","year":"2020","unstructured":"Poon, E. et al. Orally bioavailable CDK9\/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J. Clin. Invest. 130 (11), 5875\u20135892. https:\/\/doi.org\/10.1172\/jci134132 (2020).","journal-title":"J. Clin. Invest."},{"key":"31141_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020304","author":"GHS Richter","year":"2020","unstructured":"Richter, G. H. S. et al. Combined inhibition of epigenetic readers and transcription initiation targets the EWS-ETS transcriptional program in ewing sarcoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12020304 (2020).","journal-title":"Cancers (Basel)."},{"key":"31141_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174363","author":"CM Neophytou","year":"2021","unstructured":"Neophytou, C. M., Trougakos, I. P., Erin, N. & Papageorgis, P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13174363 (2021).","journal-title":"Cancers (Basel)"},{"issue":"7","key":"31141_CR40","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","volume":"22","author":"R Rathore","year":"2017","unstructured":"Rathore, R., McCallum, J. E., Varghese, E., Florea, A. M. & B\u00fcsselberg, D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 22 (7), 898\u2013919. https:\/\/doi.org\/10.1007\/s10495-017-1375-1 (2017).","journal-title":"Apoptosis"},{"issue":"5","key":"31141_CR41","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41419-022-04900-y","volume":"13","author":"MC Fitzgerald","year":"2022","unstructured":"Fitzgerald, M. C., O\u2019Halloran, P. J., Connolly, N. M. C. & Murphy, B. M. Targeting the apoptosis pathway to treat tumours of the paediatric nervous system. Cell Death Dis. 13 (5), 460. https:\/\/doi.org\/10.1038\/s41419-022-04900-y (2022).","journal-title":"Cell Death Dis."},{"issue":"2","key":"31141_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s2352-4642(19)30336-0","volume":"4","author":"DR Freyer","year":"2020","unstructured":"Freyer, D. R. et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc. Health 4 (2), 141\u2013150. https:\/\/doi.org\/10.1016\/s2352-4642(19)30336-0 (2020).","journal-title":"Lancet Child Adolesc. Health"},{"issue":"2","key":"31141_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7 (2), 27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"31141_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1479-5876-11-259","volume":"11","author":"JJ Nemunaitis","year":"2013","unstructured":"Nemunaitis, J. J. et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J. Transl. Med. 11, 259. https:\/\/doi.org\/10.1186\/1479-5876-11-259 (2013).","journal-title":"J. Transl. Med."},{"issue":"4","key":"31141_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25 (4), 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31141-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:03:40Z","timestamp":1768327420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31141-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31141"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31141-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1410"}}